Overview 2019-11-25T22:52:26+00:00

Northern Alliance Advanced Therapies Treatment Centre

The Northern Alliance Advanced Therapy Treatment Centre (NA-ATTC), formally established in March 2018, is a consortium of twenty industry, NHS and academic organisations led by Newcastle Hospitals and the Scottish National Blood Transfusion Service (SNBTS). The purpose of the centre is to develop the systems and infrastructure required to support the delivery of cell and gene therapies with the ultimate aim of increasing patient access to advanced therapy medicinal products (ATMPs) on a national level.

NA-ATTC’s vision is to increase patient access to advanced therapy medicinal products (ATMPs) regionally and nationally by growing a cost-effective clinical delivery pathway which meets the needs of the providers of advanced therapy products. The centre has a patient reach of circa 15 million spanning the North of England and Scotland and is working across two healthcare systems.

The centre will focus on all elements of the clinical delivery pathway from procurement of starting materials, near patient GMP, distribution and administration through to delivery of clinical trials and adoption and reimbursement across a range of advanced therapies and indications. This will entail the participation and collaboration of nurses, medical clinicians, hospital pharmacists, NHS managers, clinical commissioners and companies.

Location

The NA-ATTC works across the north of England (Leeds and Newcastle upon Tyne) and Scotland.

Our partners

AHSN NENC

www.ahsn-nenc.org.uk
Dr Nicola Wesley, Interim Chief Executive Officer

Alcyomics Ltd

www.alcyomics.com
Professor Anne Dickinson, Founder and Director

GE Asymptote

https://www.gelifesciences.com
Dr John G Morris, Chief Executive Officer
Bill Shingleton, Alliances Manager

Autolus Therapeutics

www.autolus.com

Christopher Vann Senior Vice President, Chief Operating Officer

Helen Delahaye, Project Manager

Chiesi Limited

http://chiesi.uk.com/rare-diseases
Julie De-Almeida, Head of Market Access UK & Ireland
Tom Chubb, Rare Disease Manager

Datatrial

www.datatrial.com
Julie Wright, Commercial Director
Jamie Pollard, Head of Software Development

NHS Greater Glasgow and Clyde

www.nhsggc.org.uk
Dr David Irvine, Consultant Haematologist
Dr Samantha Carmichael, Lead Pharmacist – Clinical Trials/R&D
Melanie McColgan, General Manager, Specialist Oncology and Clinical Haematology

Leeds Teaching Hospitals NHS Trust

www.leedsth.nhs.uk
Dr Christopher Herbert, Director of Operations for Research and Innovation
Professor Gordon Cook, Professor of Haematology and Myeloma Studies
Dr Beki James, Consultant Paediatric Haematologist
Debbie Beirne, Manager and Deputy Director of the NIHR Leeds Clinical Research Facility

Milteyni Biotec

www.milteynibiotec.com
Michele Giroux, UK General Manager

Newcastle University

www.ncl.ac.uk
https://www.ncl.ac.uk/icm/research/
https://www.ncl.ac.uk/ctf/
Professor Jim Shaw, Professor of Regenerative Medicine
Professor Anne Dickinson, Strategic Research Adviser

NHS Blood and Transplant

www.nhsbt.nhs.uk
Jon Smythe, Head of Cellular and Molecular Therapies

Dr Sandeep Kumar, Cell Therapy Advanced Specialist

NHS Lothian

www.nhslothian.scot.nhs.uk
Professor Timothy Walsh, Head of Section/Lead of Edinburgh Critical Care Research Group, R&D Director – NHS Lothian

The Newcastle upon Tyne Hospitals NHS Foundation Trust

www.newcastle-hospitals.org.uk
Neil Watson, Clinical Director of Pharmacy and Medicines Management and Co-Director of the NA-ATTC
Dr Finn Willingham, Operations Manager, NA-ATTC
David Caulfield, Assistant Director of Pharmacy, QA
Anne Black, Regional QA Specialist/Lead for Newcastle Therapeutics

RoslinCT

www.roslinct.com
Janet Downie, Chief Executive Officer

Kevin Bruce, Chief Operating Officer

Scottish National Blood Transfusion Service

www.scotblood.co.uk
Professor Marc Turner, Medical Director SNBTS and Co-Director of the NA-ATTC
Professor John Campbell, Associate Director – Tissues, Cells and Advanced Therapeutics
Ewan Morrison, Director of Pharmacy, National Services Scotland

Fisher Bioservices

www.fisherbioservices.com
Richard Bazell, Supervisor, Client Services
Christopher Stone, Supervisor, Client Services
Neil Ridley, Consultant Project Director
Luke Wilson, Lead Account Manager

TrakCel

www.trakcel.com
Dr Matthew Lakelin, Chief Scientific Officer
Ben Innes, Project Manager

University of Edinburgh

https://www.ed.ac.uk/
http://www.crm.ed.ac.uk/research/group/liver-stem-cells-and-regeneration
https://www.cvs.ed.ac.uk/research
Prof Stuart Forbes, Director, Scottish Centre for Regenerative Medicine (SCRM), WP3 Co-Lead, Clinical Advisory Group Clinician Scientist Lead
Prof Andy Baker, Scientific Advisor
Lisa Wotherspoon, Advanced Therapies Clinical Trial Coordinator

World Courier

www.worldcourier.com
Simon Ellison, Cell and Gene Therapy Service Director

Support was provided by Cell Medica (www.cellmedica.com) for the first half of the project.

Visit our other centres